Frequent deletion in the methylthioadenosine phosphorylase gene in T- cell acute lymphoblastic leukemia: Strategies for enzyme-targeted therapy

Blood

Volumn 88, Issue 8, 1996, Pages 3083-3090

  Batova, Ayse ^b   Diccianni, Mitchell B ^b   Nobori, Tsutomu ^b   Vu, Thai ^b   Yu, John ^b   Bridgeman, Louis ^b   Yu, Alice L ^a  

^a UCSD MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; ADENINE; ADENOSINE DERIVATIVE; ADENOSINE PHOSPHATE; ALANOSINE; DNA; METHIONINE; METHYLTHIOADENOSINE; PHOSPHORYLASE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CONTROLLED STUDY; EXON; GENE; GENE DELETION; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOUTHERN BLOTTING; T LYMPHOCYTE; TUMOR SUPPRESSOR GENE;

EID: 0029907953     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.8.3083.bloodjournal8883083     Document Type: Article

References (35)

1. Huffman RM: Methionine dependence in cancer cells-A review. In Vitro 18:421, 1982
2. Kamatani N, Nelson-Rees WA, Carson DA: Selective killing of human malignant cell lines deficient in methylthioadenosine phosphorylase, a purine metabolic enzyme. Proc Natl Acad Sci USA 78:1219, 1981
3. Toohey JI: Methylthioadenosine nucleoside phosphorylase deficiency in methylthio-dependent cancer cells. Biophys Res Commun 83:27, 1978
4. Kamatani N, Yu AL, Carson DA: Deficiency of methylthio-adenosine phosphorylase in human leukemic cells in vivo. Blood 60:1387, 1982
5. Fitchen JH, Riscoe MK, Dana BW, Lawrence HJ, Ferro AJ: Methylthioadenosine phosphorylase deficiency in human leukemias and solid tumors. Cancer Res 46:5409, 1986
6. Traweek ST, Riscoe MK, Ferro AJ, Braziel RM, Magenis RE, Fitchen JH: Methylthioadenosine phosphorylase deficiency in acute leukemia: Pathologic, cytogenetic, and clinical features. Blood 71:1568, 1988
7. Nobori T, Szinai I, Amox D, Parker B, Olopade OI, Buchhagen DL, Carson DA: Methylthioadenosine phosphorylase deficiency in human non-small cell lung cancers. Cancer Res 53:1098, 1993
8. Nobori T, Karras JG, Fulvio DR, Waltz TA, Pojen PC, Carson DA: Absence of methylthioadenosine phosphorylase in human gliomas. Cancer Res 51:3193, 1991
9. Smaaland R, Schanche JS, Kvinnsland S, Hostmark J, Ueland PM: Methylthioadenosine phosphorylase in human breast cancer. Breast Cancer Res Treat 9:53, 1987
10. Olopade OI, Pomykala HM, Hagos F, Sveen LW, Espinosa R III, Dreyling MH, Gursky S, Stadler WM, Le Beau MM, Bohlander SK: Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21. Proc Natl Acad Sci USA 92:6489, 1995
11. Nobori T, Takabayashi K, Tran P, Orvis L, Batova A, Yu AL, Carson DA: Genomic cloning of methylthioadenosine phosphorylase. A purine metabolic-enzyme deficient in multiple different cancers. Proc Natl Acad Sci USA (in press)
12. Zhang SY, Klein-Szanto AJP, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T, Carson DA, Ridge JA, Goodrow TL: Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 54:5050, 1994
13. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B: Deletion of p16 and p15 genes in brain tumors. Cancer Res 54:6353, 1994
14. Mon T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y: Frequent somatic mutation of the MTS1/CDK41 (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 54:3396, 1994
15. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE: Frequent somtaic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27, 1994
16. Washimi O, Nagatake M, Osada H, Ueda R, Koshikawa T, Seki T, Takahashi T: In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res 55:514, 1995
17. Okuda T, Shurtleff SA, Valentine MB, Raimondi SC, Head DR, Behm F, Curcio-Brint AM, Liu Q, Pui C-H, Sherr CJ, Beach D, Look AT, Downing JR: Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood 85:2321, 1995
18. Ogawa S, Hirano N, Sato N, Takahashi T, Hangaishi A, Tanaka K. Kurokawa M, Tanaka T, Mitani K, Yazaki Y, Hirai H: Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. Blood 84:2431, 1994
19. Fizzotti M, Cimino G, Pisegna S, Alimena G, Quartatone C, Mandelli F, Pelicci PG, Lo Coco F: Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood 85:2685, 1995
20. Otsuki R, Clark HM, Wellmann A, Jaffe ES, Raffeld M: Involvement of CSKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 on human leukemias and lymphomas. Cancer Res 55:1436, 1995
21. Cayuela JM, Hebert J, Sigaux F: Homozygous (p16INK4A) deletion in primary tumor cells of 163 leukemia patients. Blood 85:854, 1995
22. Stranks G, Height SE, Mitchell P, Jadayel D, Yuille MAR, De Lord C, Clutterbuck RD, Treleaven JG, Powles RL, Nacheva E, Oscier DG, Karpas A, Lenoir GM, Smith SD, Millar JL, Catovsky D, Dyer MJS: Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood 85:893, 1995
23. Hussussian CJ, Struewing JP, Glodstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC: Germline p16 mutations in familial melanoma. Nat Genet 8:15, 1994
24. Hatta Y, Hirama T, Millere CW, Yamada Y, Tomonaga M, Koeffler HP: Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. Blood 85:2699, 1995
25. Tyagi AK, Cooney DA: Biochemical pharmacology, metabolism, and mechanism of action of L-alanosine, a novel, natural antitumor agent. Adv Pharmacol Chemother 20:69, 1984
26. Pagani O, Sessa C, de Jong J, Kern H. Hatty S, Schmitt H, Cavalli F: Phase I studies of lometrexol (DDATHF) given in combination with leucovorin. Proc Am Soc Clin Oncol 11:109, 1992
27. Young CW, Currie VE, Muindi JF, Saltz LB, Pisters KMW, Esposito AJ, Dyke RW: Improved clinical tolerance of lometrexol with oral folic acid. Proc Am Assoc Cancer Res 33:406, 1992
28. Russo GL, Ragione FD, Utili P, Andreana A, Ruggiero G, Zappia V: Studies of human 5′-deoxy-5′-methylthioadenosine phosphorylase: Molecular properties and clinical perspectives. Adv Exp Med Biol 250:229, 1988
29. Carrera CJ, Willis EH, Chilocote RR, Kubota M, Carson DA: 5′-Deoxy-5′-methylthioadenosine phosphorylase deficiency in leukemia: Genetics and biochemical aspects. Adv Exp Med Biol 195B:643, 1986
30. Dosik GM, Stewart D, Valdivieso M, Burgess MA, Bodey GP: Phase I study of L-alanosine using a daily X 3 schedule. Cancer Treat Rep 66:73, 1982
31. Goldsmith MA, Ohnuma T, Spigelman M, Greenspan EM, Holland JF: Phase I study of L-alanosine (NSC 15353). Cancer 51:378, 1983
32. Elson PJ, Kvols LK, Vogl SE, Glover DJ, Hahn RG, Trump DL, Carbone PP, Earle JD, Davis TE: Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma. Invest New Drugs 6:97, 1988
33. Weick JK, Tranum BL, Morrison FS: The treatment of acute leukemia with continuous infusion of L-alanosine. Invest New Drugs 1:249, 1983
34. Guo H, Lishko VK, Herrera H, Groce A, Kubota T, Hoffman RM: Therapeutic tumor-specific cell cycle block induced by methionine starvation in vivo. Cancer Res 53:5676, 1993
35. Kreis W, Hession C: Biological effects of enzymatic deprivation of L-methionine in cell culture and an experimental tumor. Cancer Res 33:1866, 1973